Clinical trial

Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors

NCT06126406

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2023-11-06

PhasePHASE1

Study timeline

Study start (actual)2023-11-06Date precision: day

Registry last updated2023-11-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Gastric Cancerunresolved

Colon Cancerunresolved

Rectal Cancerunresolved

Breast Cancerunresolved

Lung Cancerunresolved

Esophagus Cancerunresolved

Cholangiocarcinomaunresolved

Pancreas Cancerunresolved

Interventions

CEA-targeted CAR-T cellsBIOLOGICAL

CEA-targeted CAR-T cellsBIOLOGICAL

Sponsors & collaborators

Chongqing Precision Biotech Co., Ltdlead sponsor

First Affiliated Hospital of Wannan Medical Collegecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06126406 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.